BiotechTube

Neladalkib (NVL-655) + Alectinib

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-small Cell Lung Cancer

Conditions

Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive

Trial Timeline

Jul 17, 2025 → Dec 1, 2029

NCT ID
NCT06765109

About Neladalkib (NVL-655) + Alectinib

Neladalkib (NVL-655) + Alectinib is a phase 3 stage product being developed by Nuvalent for Non-small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06765109. Target conditions include Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06765109Phase 3Recruiting

Competing Products

20 competing products in Non-small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
77
NBTXR3NanobiotixPhase 1/2
36
pemetrexed + erlotinibEli LillyPhase 2
52
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
69
pemetrexed + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
pemetrexed + docetaxelEli LillyPhase 3
77
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
52
PemCarbo + Pem onlyEli LillyPhase 3
77
LY2875358 + ErlotinibEli LillyPhase 2
52
AdjuvantInsight Molecular DiagnosticsPre-clinical
15
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
77
Enzastaurin HCLEli LillyPhase 2
52
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 2
44
pemetrexed + gemcitabineEli LillyPhase 2
52
ALIMTA + CarboplatinEli LillyPhase 2
52
Tomivosertib + Pembrolizumab + PemetrexedeFFECTOR TherapeuticsPhase 2
44
Divarasib + Pembrolizumab + Pemetrexed + Carboplatin + CisplatinChugai PharmaceuticalPhase 3
77

Other Products from Nuvalent

Zidesamtinib (NVL-520)Phase 1/2
38
Neladalkib (NVL-655)Phase 1/2
38
NVL-330Phase 1
30
NVL-520Pre-clinical
20
NVL-655Pre-clinical
20